Data From Intercept Pharmaceuticals (ICPT)'s Pivotal Phase 3 POISE Trial Of Its FXR Agonist Obeticholic Acid To Treat Primary Biliary Cirrhosis And Other Key Obeticholic Acid Data To Be Presented At EASL 2014
4/7/2014 8:53:16 AM
NEW YORK, April 4, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced presentations of key data at the International Liver Congress 2014, the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), being held in London, UK, at the ExCel Centre from April 9-13, 2014. Intercept will be exhibiting at booth #715 throughout the Congress.
Help employers find you! Check out all the jobs and post your resume.
comments powered by